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64Background: Chloroquine resistance in Plasmodium falciparum malaria has been associated with pfcrt 76T
(chloroquine resistance transporter gene) and pfmdr1 86Y (multidrug resistance gene 1) alleles. Pfcrt 76T
enables transport of protonated chloroquine out of the parasites digestive vacuole resulting in a loss of
hydrogen ions (H+). V type H+ pyrophosphatase (PfVP2) is thought to pump H+ into the digestive vacuole.
This study aimed to describe the geographic distribution of single nucleotide polymorphisms in pfvp2 and
their possible associations with pfcrt and pfmdr1 polymorphisms.
Methods: Blood samples from 384 patients collected (1981–2009) in Honduras (n = 35), Colombia
(n = 50), Liberia (n = 50), Guinea Bissau (n = 50), Tanzania (n = 50), Iran (n = 50), Thailand (n = 49) and
Vanuatu (n = 50) were analysed. The pfcrt 72–76 haplotype, pfmdr1 copy numbers, pfmdr1 N86Y and
pfvp2 V405I, K582R and P711S alleles were identiﬁed using PCR based methods.
Results: Pfvp2 was ampliﬁed in 344 samples. The pfvp2 allele proportions were V405 (97%), 405I (3%),
K582 (99%), 582R (1%), P711 (97%) and 711S (3%). The number of patients with any of pfvp2 405I,
582R and/or 711S were as follows: Honduras (2/30), Colombia (0/46), Liberia (7/48), Guinea-Bissau
(4/50), Tanzania (3/48), Iran (3/50), Thailand (1/49) and Vanuatu (0/31). The alleles were most common
in Liberia (P = 0.01) and Liberia + Guinea-Bissau (P = 0.01). The VKP haplotype was found in 189/194
(97%) and 131/145 (90%) samples harbouring pfcrt 76T and pfcrt K76 respectively (P = 0.007).
Conclusions: The VKP haplotype was dominant. Most pfvp2 405I, 582R and 711S SNPs were seen where
CQ resistance was not highly prevalent at the time of blood sampling possibly due to greater genetic
variation prior to the bottle neck event of spreading CQ resistance. The association between the pfvp2
VKP haplotype and pfcrt 76T, which may indicate that pfvp2 is involved in CQ resistance, should therefore
be interpreted with caution.
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Plasmodium falciparum has persisted as a major cause of human
suffering and death despite the deployment of antimalarial drugs.
A contributing factor has been the development of resistance to
antimalarial drugs such as chloroquine (CQ). For example, CQ resis-
tance was associated with 2–6-fold increase in malaria attributed
mortality (Trape, 2001). Thus, reports of developing tolerance to
currently recommended artemisinin based combination therapies
are of major concern (Dondorp et al., 2009; Noedl et al., 2008)
and an understanding of the mechanisms of drug resistance in
the malaria parasite is crucial.
Resistance to CQ appears to have developed independently in
Colombia, Venezuela, Thai–Cambodian border, Papua New Guinea
and the Philippines (Mita et al., 2009; Wootton et al., 2002). The P.
falciparum chloroquine resistance transporter (pfcrt) gene appears
to be the main determinant of CQ resistance. Speciﬁc haplotypes
at positions 72–76 are linked to the regional evolution of CQ resis-
tance (Awasthi and Das, 2013; Mita et al., 2009; Wootton et al.,
2002) and the 76T allele is essential for resistance (Djimde et al.,
2001; Plowe, 2003). Resistance has also been linked to the N86Y al-
lele of the multidrug resistance gene 1 (pfmdr1) (Babiker et al.,
2001). Resistance to CQ is associated with a loss of inherent ﬁtness
(Ord et al., 2007). It is therefore probable that compensatory muta-
tions have evolved in P. falciparum over time as have been shown
to occur in drug resistant bacteria (Jiang et al., 2008; Levin et al.,
2000).
Pfcrt is located in the membrane of the digestive vacuole (DV)
(Valderramos and Fidock, 2006) and transports protonated CQ
down its electrochemical gradient out of the DV (Martin et al.,
2009; Sanchez et al., 2007). This result in a loss of Hydrogen ions
(H+) that must be replaced if the pH is to be maintained. Thus,
the transport of H+ into the DV most probably increases when CQ
is being removed. In line with this, a 10-fold increased transcrip-
tion of a putative H+ pump located in the DV membrane has been
observed in P. falciparum exposed to CQ and a 2-fold increase when
exposed to lumefantrine (Jiang et al., 2008; Mwai et al., 2012). The
putative pump is a V type H+ pyrophosphatase (PfVP2), which con-
stitutes a novel class of H+ pump found in plants and some proto-
zoa (Luo et al., 1999; McIntosh et al., 2001; McIntosh and Vaidya,
2002; Saliba et al., 2003). The aim of this study was to explore
the role of the pfvp2 gene in antimalarial drug resistance by analys-
ing single nucleotide polymorphisms (SNPs) in pfvp2 and their
prevalence in eight different countries and possible association




















1872. Materials and methods
2.1. Biological material
Blood samples were collected from children and adults with
symptomatic or asymptomatic P. falciparum mono infections, veri-
ﬁed by microscopy, as part of clinical studies or community based
cross sectional surveys. Details of these studies are reported else-
where (Bjorkman et al., 1986; Jovel et al., 2011; Kofoed et al.,
2007; Malmberg et al., 2013; Ursing et al., 2006; Veiga et al.,
2011) and submitted for publication (Colombia study). Samples
were chosen from available regions representing several origins of
CQ resistance and the situation prior to the arrival of CQ resistance.
The studies were conducted in the following countries; Honduras
(2004–2009), Colombia (1999–2001), Liberia (1978–1981), Tanza-
nia (2008), Guinea Bissau (2001–2004), Iran (2001–2002), Thailand
(2002–2008) and Vanuatu (2002). During the collection of the sam-
ples the ofﬁcial drug policy for each country was as follow; Hondu-
ras CQ + primaquine (PQ), Colombia sulphadoxine–pyrimethaminePlease cite this article in press as: Jovel, I.T., et al. Single nucleotide polymorphi
their associations with pfcrt and pfmdr1 polymorphisms. Infect. Genet. Evol. (2(SP) + amodiaquine, Liberia CQ, Guinea-Bissau CQ, Tanzania
artemether + lumefantrine, Iran CQ + PQ, Thailand artesunate +
meﬂoquine and Vanuatu CQ + SP. Fifty samples were randomly se-
lected from each country except Honduras (N = 35) and Thailand
(N = 49) where all available samples were analysed.
2.2. Ethics
All clinical studies had regional ethical approval as follows: Eth-
ical Review Committee of Cardio Pulmonary National Institute in
Tegucigalpa, Honduras (Jovel et al., 2011), Liberian Institute of Bio-
medical Research (Bjorkman et al., 1986), Ministério da Saúde Púb-
lica in Guinea-Bissau No. 019/DHE/2004 (Kofoed et al., 2007),
National Institute for Medical Research Tanzania No. NIMR/HQ/
R.8A/Vol. IX/344 (Malmberg et al., 2013), Institute Pasteur, No.
502 in Iran (Ursing et al., 2006), and Ethical Committee of the Fac-
ulty of Tropical Medicine, Mahidol University, Bangkok, Thailand
(Veiga et al., 2011), Ethical Review Committee of the Centro Inter-
nacional de Entrenamiento en Investigaciones Médicas (CIDEIM),
Cali, Colombia. Studies in Vanuatu were approved by the Ethical
Committee in Tokyo Women’s Medical University, Tokyo, Japan.
Molecular analyses were approved by the Stockholm regional eth-
ical review board (reference number 2013/836-3).
2.3. Sample storage, DNA extraction
DNA from samples collected in Honduras, Guinea-Bissau, Tan-
zania, Iran, Vanuatu countries was extracted from the ﬁlter papers.
DNA from samples collected in Liberia was extracted from frozen
whole blood. DNA from samples collected in Thailand and Colom-
bia were extracted from culture adapted parasites. DNA extraction
was done using an ABI Prism 6100 Nucleic Acid Prep Station (Ap-
plied Biosystems, Fresno, CA) and QIAamp DNA mini kits (Qiagen,
Valencia, CA, USA) according to the manufacturer’s instructions
with minor modiﬁcations (Dahlstrom et al., 2008; Sakihama
et al., 2001). Extracted DNA was stored at 20 C.
2.4. Pfvp2 molecular analysis
Pfvp2 SNP’s were identiﬁed by searching the PlasmoDB version
7.0 in October 2009 (Accession No: PF3D7_1235200) (Aurrecoe-
chea et al., 2009). Laboratory strains from Honduras (HB3), El Sal-
vador (Santa Lucia), Brazil (7G8), Ghana (RO-33 and GHANA_1),
Sierra Leone (D6), Senegal (Senegal_3404), Africa (3D7), Indo-
china/Laos (Dd2), Thailand (K1), Vietnam (V1_S), China (FCC-2),
Papua New Guinea (D10), were aligned and SNPs identiﬁed. SNPs
405I, 582R and 711S were found in 7G8, Senegal_3404 and 3D7,
respectively. All other strains had alleles V405, K582 and P711. A
ﬁrst set of primers were used to amplify nucleotide 1112 to 2260
to include all 3 SNPs. Three primer pairs were then used to amplify
fragments that included codons 405 (nt. 1182–1291), 582 (1484–
1929) and 711(2094–2297). Primers were designed using Primer
Express software (Applied Biosystems, Fresno, CA, USA) based on
published sequence of P. falciparum (PlasmoDB Accession No.
PF3D7_1235200). Primers and PCR thermocycler conditions are
shown in Table 1. A 20 lL reaction volume for the ﬁrst reaction
contained 0.4 mM dNTPs, 2.5 mM MgCl2, 1.4 U of GoTaq DNA
polymerase, 0.8 lM of the ﬁrst set of primers and 3 lL DNA tem-
plate. Nest PCR was performed with a ﬁnal volume of 25 lL con-
taining 0.5 mM dNTPs, 2 mM MgCl2, 1 U of GoTaq DNA
polymerase, 0.5 lM of nest primers and 2 lL of 1st ampliﬁcation
product. PCR-RFLP (restriction fragment length polymorphism)
method was used to identify the SNPs 405 and 711 using restric-
tion enzymes (New England Biolabs) AseI and DpnI respectively.
Enzyme AseI and DpnI cleaved codons 405I (Ile) and 711S (Ser),





































































































Primers and thermocyler conditions for ampliﬁcation of pfvp2 SNPs.
Primer Sequence 50–30 Size (bp) PCR
1st ampliﬁcation VP2 1F TGT TGC TGT ACG TGC TAA TGT AAA AGT 1148 94 C, 30 followed by 45 cycles (94 C, 3000; 55 C, 3000; 72 C, 1’2000); 72 C, 70
VP2 1R TGT GAT CTC CTG TTA TAT TAC TCT TTA ATC CT
Nest for SNP 405 VP2 405F TGC TTT AGA AGC GGT GCT GTT A 110 94 C, 30 followed by 45 cycles (94 C, 3000; 55 C, 3000; 72 C, 30’’); 72 C, 7’
VP2 405R GAA AAG GCT AAA GTT GGA TAT AGG ATA TTA A
Nest for SNP 582 VP2 582F TGG AGA TTG TGC AGG ACA ATG T 465 94 C, 3’ followed by 45 cycles (94 C, 30’’; 50 C, 30’’; 72 C, 45’’); 72 C, 7’
VP2 582R CCC ACA ACT CCA AGT GAG CA
Nest for SNP 711 VP2 711F AAA AGT TAA AAA AAT AGC TCA TGC TTC TT 104 94 C, 3’ followed by 45 cycles (94 C, 3000; 55 C, 3000; 72 C, 3000); 72 C, 70
VP2 711R TTA CAA TGA CTG GGA AAA AAG TAG ATT C
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identiﬁed by PCR ampliﬁcation followed by sequencing. The
sequencing primer VP2 582F (50-GTG CTG AAA TTA TTG CA-30)
was used to sequence 582 codon. The sequenced fragment was
465 base pairs representing 15% of the pfvp2 gene (3174 base
pairs).
2.5. Pfcrt and pfmdr1 molecular analysis
A previously described multiplex PCR-RFLP method was used to
identify pfcrt K76T and pfmdr1 N86Y alleles (Veiga et al., 2006).
Pfcrt 72–76 haplotypes were identiﬁed by PCR ampliﬁcation fol-
lowed by sequencing (Echeverry et al., 2007). Pfmdr1 copy num-
bers were determined using real time PCR (ABI Prism 7000
Sequence Detection System) as previously described (Price et al.,
2004). Real time PCR reactions were run in triplicate for each sam-
ple. Laboratory strains 3D7, D10 and K1 with single copies of the
pfmdr1 gene were used as calibrators and FCB and Dd2 laboratory
strains with multiple copies of the gene were used as controls. The
sample copy numbers were calculated using a comparative thresh-
old method (DDCt). Assays were repeated if the following results
were obtained: copy number 1.3–1.6 and 2.3–2.6 or Ct value > 35
or standard deviation value > 0.5.
PCR and restriction products were resolved on 2% agarose gels
(Amresco, Solon, OH). All gels were stained with ethidium bromide
and visualised under UV transillumination (GelDoc, Biorad, Her-
cules, CA, USA).
2.6. Sequencing
PCR products were puriﬁed and sequenced commercially
(Macrogen Inc. Seoul, Korea). The Sequencher™ software version
4.6 (Gene Codes Corporation, Ann arbor, MI) was used for sequenc-
ing analysis. The pfvp2 and pfcrt reference sequences were taken
from P. falciparum 3D7 clone obtained from PlasmoDB version
7.0 (Accession No: PF3D7_1235200) and NCBI database (Gen-Bank
Accession No. NC_004328), respectively.
2.7. Statistics
Data were entered and analysed using Microsoft Excel 2003.
Allele proportions were calculated by dividing the number of sam-
ples with a certain allele by the number of samples with an iden-
tiﬁable allele at that position. Thus mixed infections contributed
to the proportion of both alleles. When the association between
pfvp2 alleles and alleles in pfcrt and pfmdr1 were assessed patient
samples with mixed pfcrt K76T and/or pfmdr1 N86Y alleles were
excluded. When the association between the number of patient
samples with SNPs in pfvp2 and pfcrt K76T and pfmdr1 N86Y were
assessed (Table 3 and Table S1) only patient samples in which all
alleles had been successfully identiﬁed were used. Associations
were determined using Fishers Exact test using StataCorp 12. Link-
age disequilibrium between SNPs in pfvp2 and pfcrt or pfmdr1werePlease cite this article in press as: Jovel, I.T., et al. Single nucleotide polymorphi
their associations with pfcrt and pfmdr1 polymorphisms. Infect. Genet. Evol. (2calculated. Absolute linkage was indicated by a value D = 1
whereas D = 0 indicated no linkage. A samples size of 50 was cho-
sen due to the limited number of available samples from Honduras,
Colombia, Liberia and Thailand.3. Results
Pfvp2 was successfully ampliﬁed by PCR in 344/384 (90%) pa-
tient samples. Frequencies and geographic distribution of pfvp2
V405I, K582R and P711S are shown in Table 2. The VKP alleles
were predominant with frequencies >85% in all countries. Alleles
405I + 711S were found together in 6/344 (1.7%) patient samples.
All other pfvp2 405I, 582R and 711S SNPs were identiﬁed in sepa-
rate patient samples.
Pfcrt K76T and pfmdr1 N86Y alleles were successfully ampliﬁed
in 367/385 (95%) and 358/385 (93%) patient samples, respectively.
Allele haplotypes and frequencies in each country are presented in
Table 2. Mixed K76 + 76T and/or N86 + 86Y were found in 8 sam-
ples. The proportion of P. falciparum with pfcrt K76 was signiﬁ-
cantly higher in Liberia 50/50 (100%) and Honduras 30/30 (100%)
compared to all other countries (P < 0.001). The proportion of pfcrt
K76 was also higher in Guinea-Bissau 36/50 (72%) and Tanzania
compared to Colombia, Iran, Thailand and Vanuatu (P < 0.001).
Irrespective of whether Liberia was included (119/150, 79%) or
not (69/100, 69%), the proportion of pfcrt K76 was signiﬁcantly
higher (P < 0.001) in African countries compared to Asia 2/99
(2%) or South America 0/50 (0%).
There was no statistically signiﬁcant association between any
pfvp2 allele alone and any allele in pfcrt or pfmdr1. The haplotype
pfvp2 V405, K582 and P711 occurred more frequently with pfcrt
76T (P = 0.007). Conversely, Pfvp2 405I and/or 582R and/or 711S
(i.e. not the VKP haplotype) occurred more frequently with pfcrt
K76 (P = 0.007) as shown in Table 3. Pfvp2 alleles are tabulated
against pfcrt K76T and pfmdr1 N86Y haplotypes in supplementary
material (Table S1). There were no statistically signiﬁcant
associations.
Linkage disequilibrium analyses were of most interest from
Guinea-Bissau and Tanzania as pfcrt 76K and 76T alleles showed
greatest variability there. The pfvp2 VKP haplotype was moderately
strongly linked to pfcrt 76T in Guinea-Bissau (D = 0.65) and Tanza-
nia (D = 0.68). Similarly, having pfvp2 405I and/or 582R and/or
711S (i.e. not the VKP haplotype) was moderately strongly linked
to pfcrt 76K in Guinea-Bissau (D = 0.72) and Tanzania (D = 0.65).
When data for all countries was pooled, pfvp2 405I and/or 582R
and/or 711S (i.e. not the VKP haplotype) were linked with pfcrt
76K (D = 0.5) but not with pfcrt 76T (D = 0). There was similar
and moderate linkage between the pfvp2 VKP haplotype and pfcrt
76T (D = 0.5) and pfcrt 76K (D = 0.4). No signiﬁcant linkages were
found between pfvp2 alleles and pfmdr1 N86Y.
In the respective countries, the number of patient samples with
any pfvp2 405I, 582R and/or 711S SNP(s) was as follows; Honduras
2/30 (7%), Colombia 0/46 (0%), Liberia 7/48 (15%), Guinea-Bissau







































The frequency of pfvp2 alleles in P. falciparum with varying pfcrt K76T and pfmdr1 N86Y alleles.
Pfvp2 Pfcrt Pfmdr1
K76 76T N86 86Y
V405 95% (138/145) 99% (198/201)a 97% (235/242) 98% (99/101)
K582 98% (143/146) 99% (199/200)b 99% (240/243) 99% (101/102)
P711 95% (138/146) 99% (204/207)c 96% (236/246) 99% (103/104)
VKP haplotype 90% (131/145) 97% (191/196)d 93% (224/240) 97% (95/98)
405I 5% (7/145) 1% (3/201) 3% (7/242) 2% (2/101)
582R 2% (3/146) 1% (1/200) 1% (3/243) 1% (1/102)
711S 5% (8/146) 1% (3/207) 4% (10/246) 1% (1/104)
I and/or R and/or S* 10% (14/145) 97% (5/196) 7% (16/240) 3% (3/98)
Patients with both pfcrt K76 and 76T and patients with both pfmdr1 N86 and 86Y were excluded.
a V405 occured non signiﬁcantly more often with 76T P = 0.1.
b K582 occured non signiﬁcantly more often with 76T P = 0.3.
c P582 occured non signiﬁcantly more often with 76T P = 0.06.
d The pfvp2 V405 + K582 + P711 haplotype was signiﬁcantly more common with pfcrt 76T (P = 0.007).
* i.e. not the VKP haplotype.
Table 2
Frequencies of polymorphisms in pfvp2, pfcrt 76 and pfmdr1.
Country pfvp2 pfcrt pfmdr1 pfmdr1 CNe
405I 582R 711S VKP K76a 76T N86 86Y 1 >1
Liberia 3/48 1/48 4/49 40/47 50/50 0/50 46/47 2/47 30/30
Guinea Bissau 3/50 1/50 3/50 46/50 36/50 16/50b 28/50 24/50 50/50
Tanzania 0/49 1/50 2/48 45/48 33/50 17/50b 34/50 16/50 46/46
Iran 1/50 1/50 1/50 47/50 2/50 49/50c 13/50 37/50 36/36
Thailand 1/49 0/49 1/49 48/49 0/49 49/49b 49/49 0/49 26/49 23/49
Vanuatu 0/31 0/32 0/38 28/28 1/38 38/38c 0/32 32/32 9/9
Honduras 2/30 0/30 1/30 28/30 30/30 0/30 30/30 0/30 28/28
Colombia 0/46 0/46 0/50 44/44 0/50 50/50d 50/50 0/50 44/44
a Pfcrt 72–76 haplotype was CVMNK.
b Pfcrt 72–76 haplotype was CVIET.
c Pfcrt 72–76 haplotype was SVMNT.
d Pfcrt 72–76 haplotype was CVMNT.
e CN: copy number.
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25 March 2014and Vanuatu 0/31 (0%). The proportion of patient samples with any
of pfvp2 405I, 582R and/or 711S was signiﬁcantly more common in
Liberia (P = 0.01), African countries (Liberia + Guinea-Bissau + Tan-
zania, P = 0.004), and countries where CQ resistance had not been
described at the time of blood sampling (Liberia + Honduras,
P = 0.001) compared to the other countries studied.
Frequencies of pfmdr1 with multiples copies are shown in
Table 2. None of the samples with ampliﬁcation was found to have





















Studies have previously indicated that PfVP2may be involved in
resistance to CQ and lumefantrine (Jiang et al., 2008; Mwai et al.,
2012). We therefore assessed the proportion of SNPs in pfvp2 and
their association to polymorphism in pfcrt and pfmdr1. This is, to
our knowledge, the ﬁrst such report. The most striking result was
the lack of variation of the pfvp2 alleles studied. Only 26 SNPs in
20 samples were found among 344 samples (including sequencing
of approximately 15% of the gene) collected in 8 countries with
varying origins and proportions of CQ resistant P. falciparum at
the time of blood sampling. The results thus suggest that the parts
of the pfvp2 gene that were analysed are conserved.
Despite the lack of variation, the pfvp2 V405, K582 and P711
haplotype was found to be associated with and linked to pfcrt
76T. As pfcrt 76T is essential for CQ resistance these results sug-
gest that the pfvp2 V405, K582 and P711 haplotype might be
associated with the development of CQ resistance. Previously,
pfvp2 up-regulation was shown to occur in P. falciparum underPlease cite this article in press as: Jovel, I.T., et al. Single nucleotide polymorphi
their associations with pfcrt and pfmdr1 polymorphisms. Infect. Genet. Evol. (2CQ pressure (Jiang et al., 2008). This was proposed to be due
to increased H+ transport into the parasite DV to compensate
for H+ loss when CQ was transported out (Martin et al., 2009;
Sanchez et al., 2007). Assuming that pfvp2 functions as suggested
by Jiang et al., the results of this study indicate the pfvp2 V405,
K582 and P711 haplotype provides a more efﬁcient H+ pump
than the IRS haplotype in P. falciparum with the pfcrt 76T geno-
type. However, given the high frequency of VKP in Liberia and
Honduras where pfcrt K76 prevalences were 100% and CQ resis-
tance had not been described (when blood samples were col-
lected), the association between the VKP haplotype and pfcrt
76T should not be over emphasised.
There was also an association and linkage between pfvp2 405I,
582R and/or 711S and pfcrt K76. These alleles were signiﬁcantly
more common in Liberia in patient samples collected before CQ
resistance reached the country (Bjorkman et al., 1985). Though
not signiﬁcant, the only pfvp2 405I, 582R and/or 711S alleles found
in the Americas were detected in Honduras from where indigenous
CQ resistant P. falciparum have to date not been reported (Jovel
et al., 2011). The presence of these alleles in CQ sensitive settings
in both Africa and the Americas suggests that there was a larger
variation in the pfvp2 gene prior to the spread of CQ resistance, a
bottleneck event for P. falciparum that reduced its genetic diversity
(Wootton et al., 2002).
Fourteen of 20 patient samples with pfvp2 405I, 582R and/or
711S came from African countries of which, 11/20 came fromWest
Africa. This might suggest that the association between pfvp2 and
pfcrt is incidental possibly due to geographical variation. However
the pfvp2 SNPs were also linked to pfcrt 76K in Tanzania. An alter-
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pling and the proportion of CQ resistant P. falciparum had remained
relatively low 25% in Guinea-Bissau (Ursing et al., 2009). There
had thus been less selective pressure on pfvp2 in these two coun-
tries and P. falciparum had not passed through the parasite popula-
tion bottle neck of CQ resistance spreading.
Sequencing of the pfcrt 72–76 haplotype identiﬁed the expected
region speciﬁc haplotypes. There was no association between CQ
resistance associated pfcrt 72–76 haplotypes CVIET or SVMNT
and the pfvp2 alleles suggesting that the association between pfvp2
alleles and pfcrt 76T was independent of the origin of CQ resistant
P. falciparum. However, we did not have access to samples repre-
senting all origins of CQ resistance.
To conclude, the pfvp2 V405, K582 and P711 alleles were pre-
dominant throughout the eight countries studied. An association
between the pfvp2 405 V, 582 K and 711P haplotype and pfcrt
76T was detected. These observations are in line with previous
data indicating that PfVP2 may have a role in CQ resistance (Jiang
et al., 2008). However, pfvp2 SNPs were only found in 20/385
patient samples. The correlations found should therefore be inter-
preted with caution.
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